Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias
Rory S Care, Peter J M Valk, Anne C Goodeve, Faisel M Abu-Duhier, Wendy M C Geertsma-Kleinekoort, Giu A Wilson, Mamdooh A Gari, Ian R Peake, Bob Löwenberg, John T Reilly, Rory S Care, Peter J M Valk, Anne C Goodeve, Faisel M Abu-Duhier, Wendy M C Geertsma-Kleinekoort, Giu A Wilson, Mamdooh A Gari, Ian R Peake, Bob Löwenberg, John T Reilly
Abstract
DNA from 110 adult de novo acute myeloid leukaemia (AML) patients exhibiting either inv(16) (n = 63) or t(8;21) (n = 47) was screened for mutations in the c-KIT (exon 8 and Asp816) and FLT3 (ITD and Asp835) genes. c-KIT exon 8 mutations were found in 15/63 (23.8%) inv(16) patients and 1/47 (2.1%) t(8;21) patients. c-KIT Asp816 mutations were present in 5/63 (7.9%) inv(16) AML and 5/47 (10.6%) t(8;21) AML. FLT3 mutations were identified in five patients (7.9%) with inv(16) and three patients (5.6%) with t(8;21) AML. All mutations were mutually exclusive; 40% of inv(16) AML patients possessed either a c-KIT or FLT3 mutation. c-KIT exon 8 mutations were shown to be a significant factor adversely affecting relapse rate.
Source: PubMed